Journal article

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Sai-Hong Ignatius Ou, Eunice L Kwak, Christina Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W Clark, D Ross Camidge, Benjamin J Solomon, Robert G Maki, Yung-Jue Bang, Dong-Wan Kim, James Christensen, Weiwei Tan, Keith D Wilner, Ravi Salgia, A John Iafrate

Journal of Thoracic Oncology | ELSEVIER SCIENCE INC | Published : 2011

DOI: 10.1097/JTO.0b013e31821528d3

Grants

Awarded by Pfizer, Inc.

Funding Acknowledgements

Supported by (A8081001, ClinicalTrials.gov identifier NCT00585195) Pfizer, Inc. Ravi Salgia, MD, PhD, is supported by grant 5RO1CA125541-05.

Citation metrics

301Web of Science
322Scopus

Keywords

Leads
Receptors, Growth Factor
Science & Technology
Met Polysomy
Pyrazoles
Resistance
18(f)-Fdg Pet/ct
Pyridines
Anaplastic Lymphoma Kinase (alk) Re-Arranged Nsclc
Receptor Protein-Tyrosine Kinases
Gene Copy Number
Aged
Life Sciences & Biomedicine
Mutations
Crizotinib
Antibodies, Monoclonal, Humanized
Oncology
Survival
Female
De Novo Met Amplification Nsclc
Non-Small Cell Lung Cancer
Respiratory System
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Antibodies, Monoclonal
Proto-Oncogene Proteins C-Met
Bevacizumab
Gene Amplification
Crizotinib (pf02341066)
Treatment Outcome
Deoxycytidine
Gefitinib
Epithelial-Mesenchymal Transition
Anaplastic Lymphoma Kinase
Humans
Protein Kinase Inhibitors
Carboplatin